To investigate the functional consequences of the single nucleotide polymorphism rs4648889 in a putative enhancer upstream of the RUNX3 promoter strongly associated with ankylosing spondylitis (AS).
INTRODUCTION (251)
Characterised by prominent axial skeletal involvement and enthesitis ankylosing spondylitis (AS) is the archetypal inflammatory spondyloarthropathy (SpA). It has a complex aetiology with more than a hundred genetic influences. [1, 2] Only a few of the associated single nucleotide polymorphisms (SNP) cause obvious functional amino acid substitutions, such as rs11209026 that impairs signalling through the interleukin (IL) 23 receptor. [3] In contrast, most disease-associated SNPs probably exert a regulatory role on gene expression through epigenetic mechanisms, such as differential binding of transcription factors (TF) or microRNAs. [4] Here we report the extended effects on TF binding of a SNP (rs4648889) in a putative regulatory element (enhancer) upstream of the RUNX3 gene, which is strongly associated with AS. RUNX3 is a key regulator of several lineage-specific developmental pathways, including T-cells, and has potential roles in infection, immunity and cancer. [5, 6] We previously showed that rs4648889 influences RUNX3 expression in CD8+ T-cells by altered binding of the interferon regulatory factor (IRF) 4 TF. [7] The effects of TF complexes bound to DNA may depend on the overall complement of components recruited to them. We therefore used a DNA pulldown approach combined with quantitative mass spectrometry to define the full range of interacting TF partners binding at rs4648889 and to refine our previous observations relating to IRF4. [7, 8] Here we show that IKZF3 (the zinc finger protein aiolos) and several factors of the NUcleosome Remodeling Deacetylase (NuRD) complex (a gene repressor complex involved in chromatin remodelling) show differential allelic binding at rs4648889 and that IRF5 is also involved.
RESULTS (565)

SNP-based TF capture and analysis by label-free mass spectroscopy
Principal component analysis (PCA) showed well-separated clusters corresponding to the different rs4648889 genotypes ( Fig 1A) . Significant differential binding was apparent for 38 proteins (false discovery rate <0.05) between the protective "G" allele and the AS-risk associated "A" allele ( Fig 1B and Suppl Table 1 ). Reactome pathway analysis revealed significant enrichment for proteins involved in immunity, chromatin remodelling/histone deacetylation, RNA polymerase II transcription initiation and RUNX3 regulation ( Fig 1C) . Unsupervised hierarchical clustering demonstrated distinct DNA/protein "interactome" profiles for these two alleles ( Fig 1D) .
Identification of IKZF3 and NuRD co-factors by Mass Spectrometry (MS)
Specific DNA-binding motifs encompassing rs4648889 were found for IKZF3 and Chromodomain-Helicase-DNA-binding protein 4 (CHD4) (Fig 2A) . Analysis of publicly available ChIP-seq data (ENCODE https://genome.ucsc.edu/ENCODE/) confirmed strong peak signals both for IKZF factors and CHD4 in the vicinity of rs4648889, in lymphoblastoid cell lines ( Fig 2B) . The pull-down experiments (Fig 2C and Suppl Table 2 ) identified all the previously described members of the NuRD repressor complex. [9] The label-free quantitation showed that IKZF3 was significantly more abundant with the AS-risk A allele compared to the protective G allele (3.7-fold, p<0.05). Binding to the A allele was also significantly increased for several components of the NuRD complex, including CHD4 (3.6fold, p<0.05), Retinoblastoma-Binding Protein 4 (RBBP4, 4.1-fold, p<0.03), and Methyl-CpG-Binding Domain protein 2 (MBD2, 1.5-fold, p=0.05). This trend continued for other NuRD proteins, including Lysine-Specific histone Demethylase 1 (KDM1A) and the Histone Deacetylases HDAC1 and HDAC2 (non-significant increased binding to the A allele 2.4-, 16.1-and 16.2-fold, respectively).
IKZF3-NuRD-RUNX3 pathway analysis
There was significant enrichment for protein-protein interactions among the differentially abundant NuRD-related proteins, IKZF3 and RUNX3 (p<7.4x10 -9 ; Suppl Fig 2A) , relating to transcription, DNA-binding and histone deacetylation (respectively p=6.3x10 -5 , p=6.1x10 -6 , p=3.6x10 -9 ; Suppl Fig 1B) in the GO molecular functions and biological processes function (Suppl Fig 2B) .
Validation of differential binding for IKZF3, CHD4 and RBBP4
The MS results were validated by three further experimental approaches. First, Western blots (WB) of the pulled-down eluates confirmed the preferential binding of IKZF3, CHD4 and RBBP4 to the AS-risk A allele (Fig. 3A) . Second, the impact of rs4648889 on TF binding was confirmed in EMSA performed with nuclear extract (NE) from Jurkat T-cell line. The intensity of the DNA/NE complex was less with the AS-risk allele than the protective allele (G=68.1 ± 1.5 vs A=21.3 ± 3.7; p=0.002; n=3). A supershifted band more evident with the AS-risk A allele was induced by antibodies against IKZF3, CHD4 ( Fig 3B, lanes 9 and 10) and RBBP4 ( Fig 3D, lane 8) confirming the interaction of these TF with the 50bp sequence encompassing rs4648889. Third, allele-specific ChIP-qPCR of freshly isolated CD8+ T-cells from blood cones, heterozygous for rs4648889 (3 independent experiments) showed enhanced relative enrichment for IKZF3, CHD4, RBBP4 (p=0.04, p=0.07 and p=0.06, respectively) to the AS-risk A allele ( Fig 3E) .
Interferon regulatory factor 5 (IRF5) preferentially binds to the G allele at rs4648889 IRF4 was not among the 38 proteins displaying significant differential allelic binding using this approach but IRF5 bound preferentially to the AS-protective G allele (fold change 8.2, p=0.003). IRF5 binding to rs4648889 was therefore also further evaluated. EMSA revealed markedly greater binding of Jurkat NE to the G allele, which was significantly reduced by IRF5 antibody (Fig 3 F & G) . ChIP-qPCR was also suggested allelic imbalance with a nonsignificant enhanced enrichment for the protective G allele ( Fig 3H, p=0 .08).
DISCUSSION (643)
We identified a complex network of TFs and chromatin regulatory proteins [10, 11] interacting with a putative cis-regulatory (enhancer) element upstream of the distal RUNX3 promoter, which is implicated in the aetiology of AS. Many of these proteins exhibit differential allelic binding in vitro to a short DNA sequence in this region around rs4648889. In particular, IKZF3 (aiolos), a global regulator of chromatin architecture, [12] binds preferentially to the AS-risk allele. The Ikaros family of TFs (including aiolos) play important roles in lymphocyte development and are often associated with the NuRD complex, an ATPdependent chromatin-remodelling complex involved in transcriptional repression. [13, 14] Our DNA pull-down approach identified most of the components of the NuRD complex active at this locus (CHD4, MBD2, RBBP4, HDAC1, HDAC2 and KDM1A), all of which exhibit the same preferential binding to the A allele. Results consistent with these were also obtained by WB, EMSA and ChIP-qPCR, suggesting that transcriptional repression [7] associated with the NuRD complex is implicated in the pathogenesis of AS perhaps by regulating RUNX3 expression in CD8+ T-cells. Interestingly certain T-cell memory phenotypes are reliant on the recruitment of Eomesodermin (another TF encoded at the AS-associated EOMES locus) [1] that binds mostly to RUNX3 bound enhancers, such as HDACs and CHD4. [15] Rheumatologists also have an interest in CHD4 because it is one of the target antigens for autoantibodies (anti-Mi2) in about 20 per cent of cases of dermatomyositis. [16] However, the relevance of these antibodies to the inflammatory processes of myositis or the malignancies commonly associated with dermatomyositis is unclear.
IRF5 was also among the 38 factors with significant differential allelic binding (p=0,003) but in this case the binding was significantly higher to the protective G allele. Previously we identified IRF4, another IRF family member, binding to this region [7] but we could not identify IRF4 in our pull-down experiments here. Overall our results suggest that both factors bind to the DNA region upstream RUNX3 but suggest either differential activity between IRF4 and IRF5 or lower expression of IRF4, which was not therefore detectable by mass spectrometry. The consensus IRF motifs (GGAAC/GAAAC) overlap those for CHD4 and IKZF3 (aiolos) at rs4648889 (Figure 2A) , which raises the possibility of mutually antagonistic effects on DNA binding. IRF5 is of considerable interest in inflammatory states: it plays a central role in the induction of inflammatory cytokines, such IL6, IL12, IL23 and tumour necrosis factor α. [17] It is also a key factor in determining inflammatory macrophage phenotypes in response to stimulation by interferon γ and granulocyte-macrophage stimulating factor, which is now thought to be a key factor in the development of AS. [18] IRF5 is also strongly associated genetically with other inflammatory disorders, including rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis and inflammatory bowel disease, where it is associated with insertion/deletion mutations creating an Sp1 binding site that upregulates IRF5 expression. [19] IRF5 is therefore an attractive target for treatment of these disorders and could certainly be relevant for AS. The potential benefits of modulating IRF5 expression, its post-translational modification and/or functional interactions with its protein partners for therapeutic benefit have been extensively discussed elsewhere. [17] Increased binding of the chromatin reader BRD4, also to the ASprotective allele G (Bromodomain Containing 4, see Supplementary Table 1 ), reinforces the likely contribution to AS of factors involved in transcriptional control and epigenetic regulation at RUNX3. [20] The approach we have adopted here is a first step towards understanding the mechanisms underlying one of the strongest genetic associations with AS and the role of RUNX3 in its pathogenesis. In this paper and in previous work [7] we have demonstrated the impact of AS-associated SNPs on TF binding to the enhancer-like region upstream of RUNX3 and on RUNX3 expression in CD8+ T-cells. [7] Further clarification of the pathways involved is needed but these results suggest that RUNX3 related pathways and IRF5 represent important potential therapeutic targets for the treatment of AS.
KEY MESSAGES
What is already known about this subject?
• Ankylosing spondylitis (AS) has a strong genetic contribution.
• RUNX3, a transcription factor (TF) involved in CD8+ T-cell development and differentiation, has one of the strongest genetic associations with AS • rs4648889, a single nucleotide polymorphism located upstream of the promoter influences RUNX3 expression in CD8+ T-cells by altering transcription factor binding What does this study add?
• We identified many proteins, including transcription factors bound to the region encompassing rs4648889 using a DNA pull-down approach coupled with quantitative Mass Spectrometry • IRF5, IKZF3 and members of the gene repressor Nucleosome Remodelling Deacetylase (NuRD) complex exhibit differential binding between the AS-risk and AS-protective alleles.
How might this impact on clinical practice or future developments?
• Differential binding of transcription factors at rs4648889 suggests that regulation of RUNX3 expression by IRF5 and the NuRD complex are important in the pathogenesis of AS Supplementary Table 2 . Label free quantification of IRF5, IKZF3 and NuRD complex factors identified with M/S approach. Label free quantification after median subtraction of IKZF3, IRF5 and the NuRD complex factors obtained from three independent experiments. NuRD proteins showed greater abundance with the "A" allele, highlighted in light blue. IRF5 showed significantly more
METHODS (863) Methods are published online
DNA-affinity capture 100nM anti-sense single-stranded oligonucleotides (50bp) were 3'-end biotinylated, mixed and annealed at room temperature (RT) for 1hr with the sense oligonucleotide. Streptavidincoated beads (Dynabeads M-280, catalogue number 11205D, Thermo Fisher Scientific, Waltham, Massachusetts, USA) were equilibrated with six washes with wash buffer (10.0 mM Tris-HCl pH 7.4, 2.0 M NaCl, 1mM EDTA). Biotin-labelled DNA was incubated with streptavidin-coated beads for 1 hour at RT, on a rotary wheel. Three successive washes were performed to eliminate the unbound biotinylated-DNA. Nuclear extract (NE) (500μg) from CD8+T-cells was pre-incubated on ice for 20 min in mobility shift essay (EMSA) binding buffer (100mM Tris, 500mM KCl, 10mM DTT; pH 7.5) and then incubated with beads for 1 hour at 21 o C on a rotary wheel. Beads were then stringently washed six times: once with 500ul of EMSA binding buffer, three times with wash buffer + 0.1% Tween20, twice with 50mM NH 4 HCO 3 . Beads were then re-suspended in sample buffer containing 10mM EDTA, 1% SDS and Benzonase (1U) for 60 minutes, at RT on a rotary wheel, in order to separate the DNA-protein complexes from the beads. Magnetic separation was used to separate the biotinylated nucleic acid from the supernatant. Benzonase was used to eliminate DNA and other contaminants to ensure that only the protein complexes were collected. Overview of the experimental approach is showed in Supplementary Figure 1 .
Liquid chromatography mass spectrometry
Protein samples were prepared for mass spectrometric analysis by tryptic digest as described previously [1] . Briefly, proteins were reduced and alkylated (DTT/Iodoacetamide) before digest with Trypsin (Promega) and desalting of peptides using C18 material (Sola, Thermo-Fisher). Peptides were then analysed on a nano LC-MS/MS platform consisting of Q-Exactive mass spectrometer and nano UPLC (both Thermo Fischer) [2] . Chromatographic separation of peptides was achieved on a easyspray column (75umx 500mm) using a gradient from 5% DMSO in 0.1% formic acid/5% Acetonitrile to 5%DMSO in 0.1% formic acid in 35% Acetonotrile. MS parameter were used as described earlier. Quantitative data are derived from the number of MS/ MS spectra per peptide (spectral counting) or the integrated peak area of the ion chromatogram of a specific peptide as reported by ProgenesisQI (Waters, version 2.0) using default parameters. Protein IDs were generated with Mascot at 1% FDR and peptide score cut-off at 20 against a Uniprot human database. All proteomics data is publicly available through the Pride consortium [3] .
Data visualization, STRING and Gene Ontology (GO) analysis
Proteomics data were visualized with Qlucore Omics Explorer (version 3.7) to obtain principal component analysis (PCA) and unsupervised hierarchical clustering. Cytoscape (v3.7.0) was used to analyse the MS data in defining Gene Ontology (GO) categories and sub-groups (http://geneontology.org/). The Reactome [4] database was used to integrate pathway analysis. The R package was used to create Volcano plots. String (v 11.0), a database of known and predicted protein-protein interactions (PPI), was used to define the PPI enrichment of the differentially abundant proteins identified.
Epigenetic database interrogation
A combination of epigenetic data from the ENCODE [5] and Roadmap Epigenomics Projects [6] was used to analyse the region encompassing SNP rs4648889, in particular ChIP-seq peaks for IKZF and CHD4 transcription factor (TF) on lymphoblastoid cell lines.
CD8+ T-cells isolation and nuclear extract preparation
CD8+ T-cells were isolated from peripheral blood mononuclear cells (PBMCs) from buffy coat using a CD8+ T-cell isolation kit (Miltenyi, Bisley, Surrey, UK). CD8+ T-cells were resuspended at 1×10 6 /mL in pre-warmed Roswell Park Memorial Institute (RPMI) medium supplemented with 10% foetal bovine serum, penicillin/streptomycin and L-glutamine. After 4 hours resting the cells were then harvested.
Electrophoretic mobility gel shift assay (EMSA)
EMSA were performed as previously described [12] . Briefly, the DNA probes were mixed and annealed at room temperature for 1 hour. For super shift assays, 5μg of nuclear extract (NE) obtained from Jurkat cells were first incubated (20 min) with a specific antibody, then the NE-antibody complex was incubated (20 min) with biotinylated DNA and run on retardation gels. Full list of antibodies and DNA probes are available in Supplementary Table  3 and 4.
Western blot assay
Eluted samples were separated by SDS-PAGE, transferred onto nitrocellulose membranes (Bio-Rad Laboratories Berkeley, California, USA), and incubated overnight at 4°C variously with primary antibodies against IKZF3, CHD4, RBBP4. Appropriate horse-radish peroxidaseconjugated secondary antibody was used and signals detected with enhanced chemiluminescence (ECL) method (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
ChIP-qPCR
ChIP was performed using ABI ViiA 7 PCR device (Applied Biosystems, Paisley, UK) using the iDeal ChIP-seq kit for Transcription Factors (catalogue number C01010055, Diagenode, Liege, Belgium). For each ChIP, 2.5×10 6 CD8+ T-cells were used. Three independent qPCR experiments were performed using allele-specific primers for rs4648889 (primers sequence available here [12] ). We used CD8+ T-cells (n=3) of known genotype (heterozygous for rs4648889) from buffy coat blood cones to compare the impact of the AS-risk and -protective alleles on relative enrichment. We normalized all of our ChIP-qPCR data against a 1% input control as per manufacturer instructions. Data were visualized with Prism version 8.0.2. The following ChIP grade antibodies were used: RBBP4 (catalogue number ab79416, Abcam, Cambridge, UK), CHD4 (catalogue number 14173-1-AP, Proteintech Europe, Manchester, UK), IKZF3 (catalogue number ab139408, Abcam, Cambridge UK), IRF5 (catalogue number E1N9G Rabbit mAb #13496) and IgG (catalogue number K02041008, Diagenode, Liege, Belgium).
Patient and Public Involvement
The database used in the study was developed with direct involvement of the National Ankylosing Spondylitis Society through its members, trustees and medical advisory committee. All aspects of this work are regularly reported to the members of the Society through its bimonthly newsletter and annually at the AGM and members' day. 
